Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334918 · ClinicalTrials.gov registry record · Phase 2
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT01334918 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 124 participants.
The verdict
NCT01334918, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.
Interventions
- PROCEDURE Single Photon Emission Computed Tomography
- DRUG regadenoson
- RADIATION technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
- RADIATION Contrast
- PROCEDURE Multidetector Computed Tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2011-04-26 |
| Est. Completion | 2012-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334918
The ClinicalTrials.gov registry entry for NCT01334918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Single Photon Emission Computed Tomography is the first listed.
NCT01334918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01334918 about?
NCT01334918 is a clinical study titled "A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)". The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.
What is the current status of trial NCT01334918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2011-04-26. Estimated completion is 2012-07-02.
What interventions are being tested in trial NCT01334918?
The interventions under investigation include: Single Photon Emission Computed Tomography (PROCEDURE), regadenoson (DRUG), technetium Tc99m sestamibi /technetium Tc99m tetrafosmin (RADIATION), Contrast (RADIATION), Multidetector Computed Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT01334918?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.